Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics (Nasdaq: SLN) will receive a $2 million milestone payment from Hansoh Pharma for achieving a second undisclosed milestone in their collaboration.
June 24, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics will receive a $2 million payment from Hansoh Pharma for achieving a second milestone in their collaboration, which could positively impact SLN's revenue and investor sentiment.
The $2 million payment from Hansoh Pharma is a direct financial benefit to Silence Therapeutics, which could improve its revenue stream and positively influence investor sentiment. The achievement of a milestone also indicates progress in their collaboration, which is a positive signal for the company's future prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100